The Medical Letter on Drugs and Therapeutics
ONLINE
ONLY
ARTICLE
May 25, 2015
View Complete Issue         Table of Contents 2019 
Afatinib (Gilotrif) for Advanced Non-Small Cell Lung Cancer (online only)
Subscribers: Log in to read full article.  Not a subscriber?  Subscribe or purchase article.
Afatinib (Gilotrif) for Advanced Non-Small Cell Lung Cancer (online only)
May 25, 2015 (Issue: 1469)
The FDA has approved afatinib (Gilotrif — Boehringer Ingelheim), an oral epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor, for first-line treatment of patients with metastatic non-small cell lung cancer (NSCLC) whose tumors...more
The Medical Letter is a subscriber-funded nonprofit organization that publishes critical appraisals of new prescription drugs and comparative reviews of drugs for common diseases.

Would you like to read the rest of this article?  Gain access below.

Subscribe
Subscriptions to The Medical Letter on Drugs and Therapeutics include:
  • Print version published and mailed biweekly (26 issues/year)
  • Unlimited online access to current and past issues (1988 - present)
  • Mobile App
  • FREE online per issue CME/CE
Purchase this article:
Title: Afatinib (Gilotrif) for Advanced Non-Small Cell Lung Cancer (online only)
Article code: 1469e
 Electronic, downloadable article - $45


Gain access through your organization
Ask your librarian to consider an Institutional Subscription to The Medical Letter.